Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
3
60%
Ph phase_3
1
20%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Not yet recruiting2
Active, not recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting120%
not_yet_recruiting240%
recruiting120%
completed120%

Recent Activity

2 active trials
Showing 5 of 5
not_yet_recruitingphase_2

Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

NCT07459452
not_yet_recruitingphase_3

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

NCT07402213
active_not_recruitingphase_2

Trial of JYB1904 in Patients With Allergic Asthma

NCT06438757
recruitingphase_2

Trial of JYB1904 in Chronic Spontaneous Urticaria.

NCT06509334
completedphase_1

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

NCT05449535

Clinical Trials (5)

Showing 5 of 5 trials
NCT07459452Phase 2

Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

Not Yet Recruiting
NCT07402213Phase 3

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

Not Yet Recruiting
NCT06438757Phase 2

Trial of JYB1904 in Patients With Allergic Asthma

Active Not Recruiting
NCT06509334Phase 2

Trial of JYB1904 in Chronic Spontaneous Urticaria.

Recruiting
NCT05449535Phase 1

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5